India

Bharat Biotech | Approval of third dose testing in clinical trials of India Biotech vaccine

Written by admin

Bharat Biotech | Approval of third dose testing in clinical trials of India Biotech vaccine

New Delhi: The number of corona patients in the country is steadily increasing. As a result, the government has stepped up vaccination of corona. Now there is big news regarding Bharat Biotech vaccine. A third dose will also be given in the clinical trial of Bharat Biotech vaccine. It is approved by the Central Drugs Standard Control Organization.

This is an extension of the second phase of the corona vaccine. This is the third dose to be given six months after the second dose of corona vaccine. He will be followed up for the next six months. Bharat Biotech has stated that the dose of vaccine in this third trial will be six micrograms. & Nbsp;

The effect of the dose of the first and second vaccines of Bharat Biotech is 81%. In such a case, if the third dose of the vaccine is given, the effect is likely to increase, experts say. Therefore, it is said that this third trial may start soon. The third phase vaccine will be tested on volunteers who were tested in the second phase. The company has added 81,466 new corona patients in the last 24 hours and 469 deaths. Is done. Also, 50,356 patients have been cured in the last 24 hours. & Nbsp; The number of corona patients in the country is increasing alarmingly every day. Therefore, the central government has taken an important decision. The central government has said that public and private vaccination centers will be vaccinated on all holidays, including gazetted holidays, in April.

Important News: & nbsp;

#Bharat #Biotech #Approval #dose #testing #clinical #trials #India #Biotech #vaccine

About the author

admin

Leave a Comment